Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
TARGETING INHERITED CANCER SYNDROMES (INCANTAR)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Physiology in Health, Disease and Ageing
Panel description: Organ and tissue physiology, comparative physiology, physiology  of ageing , pathophysiology, inter - organ and tissue communication, endocrinology, nutrition,  metabolism, interaction with the microbiome, non -communicable diseases including cancer (and except disorders of the nervous system  and immunity -related diseases)
Countries involved: Italy
Call: ERC ADVANCED GRANTS (ERC-2022-ADG, 2022)
Start date: 2023-09-01
End date: 2028-08-31
Duration (months): 60.0
Total project cost (EUR): 2496625.0
EU funding (EUR): 2496625.0
Participants: 2
Project status: SIGNED

Transcription factors EB and E3 (TFEB and TFE3), members of the MiT-TFE family, are master controllers of lysosomal biogenesis and autophagy. The activity of TFEB and TFE3 is regulated by mechanistic Target Of Rapamycin Complex 1 (mTORC1), a central hub of cell metabolism, which inhibits their cytoplasm-to-nucleus translocation. We recently discovered that mTORC1 phosphorylates TFEB and TFE3 via a non-canonical TORC1 (NC-mTORC1) signaling mechanism, providing the first evidence that mTORC1 can produce specific responses to different environmental cues by differential substrate phosphorylation. We and others recently discovered that dysregulation of NC-mTORC1, leading to constitutive activation of TFEB/TFE3, is the main driver of the renal cystic and tumorigenic phenotype of inherited cancer syndromes Birt-Hogg-Dube' (BHD) and Tuberous Sclerosis Complex (TSC). Remarkably, deletion of TFEB completely rescued renal cystogenesis and tumorigenesis in BHD and TSC mouse models. Furthermore, additional types of cancer have been associated to induction of TFEB/TFE3, suggesting that this may be an emerging mechanism of tumorigenesis. In INCANTAR (INherited CANcer TARgeting) we aim to identify novel regulators of TFEB/TFE3 factors by CRISPR screening and protein interactome analyses, which may reveal new therapeutic targets. We also plan to thoroughly characterize the pathogenic role of TFEB and TFE3 in TSC and BHD using transgenic mice and kidney and brain organoids. Finally, we will explore novel therapeutic strategies for TFEB/TFE3 driven diseases, such as selective ablation of cells expressing GPNMB, a sensitive transcriptional target of MiT-TFE factors, and drug screening for MiT-TFE inhibitors using a newly developed MiT-TFE transcriptional reporter. These studies will shed new light on the mechanisms underlying the pathogenic role of MiT-TFE factors and are likely to generate novel therapeutic tools for several cancer-associated conditions.

Keywords: mtorc1,lysosome,tuberous sclerosis,autophagy,kidney cancer,cell signalling,gene networks
MorphoPace: Understanding the conserved mechanisms pacing morphogenesis (MorphoPace)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Austria
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2026-09-01
End date: 2028-08-31
Duration (months): 24.0
Total project cost (EUR): 306206.74
EU funding (EUR): 214344.72
Participants: 1
Project status: SIGNED

Animal development relies on the timely succession of different differentiation, in which cells acquire a certain identity and function, and morphogenetic, in which cells are placed in the part of the animal body, steps. These conserved steps follow a highly stereotypical timing among animals of the same species, but, remarkably, it varies significantly across species. For example, gastrulation, the first morphogenetic movement shaping the embryo, takes 2.5x longer in medaka (Oryzias latipes) than zebrafish (Danio rerio) in the same conditions. Although these differences are well known, it remains unclear how time is kept during development. Recent work has shown that molecular differences between species define the pace of differentiation. It is unclear, however, how these scale up to set the pace of morphogenesis, a collective process that happens across embryos, and set by active cell movements and resisting tissue material properties. With this project, I aim to understand these pace morphogenesis, by comparing gastrulation in two fish species: zebrafish and medaka. Since the latter species remains undescribed, I will first characterize mesendoderm internalization, the opening act of gastrulation. I will map single-cell properties and tissue-scale features, and use a theoretical physics model to make predictions about timing differences between species. Secondly, I will define whether pace is intrinsic to the cells, or set by the native environment, by transplanting cells between embryos of different species, and using zebrafish-medaka hybrids. Finally, I will manipulate the pace of internalization by modulating both intrinsic forces and the tissue state. Altogether, this project will build a way to understand morphogenesis by comparing different fish species, which have broad implications in biology, physics and evolution by uncovering how embryos time development across teleost fish, the largest and most diverse class of vertebrates in the planet.

Keywords: developmental biology,morphogenesis,tissue mechanics
IONIC Liquid Mediated Synthesis of Zeolite-Supported Metal Oxide Based CATalysts for Converting CO2 to Dimethyl ether (IONICCAT)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Belgium
Call: MSCA Postdoctoral Fellowships 2021 (HORIZON-MSCA-2021-PF-01, 2021)
Start date: 2023-04-01
End date: 2025-03-31
Duration (months): 24.0
Total project cost (EUR): 191760.0
EU funding (EUR): 191760.0
Participants: 1
Project status: CLOSED

Making dimethyl ether (DME) from hydrogenating CO2 has attracted great interest as DME is a good propellant, coolant and clean fuel. This process can break the thermodynamic restriction that exists for methanol synthesis from CO2 and improve the conversion of main greenhouse gas. The synthesis of well-controlled shapes of solid materials in nano-size using ionic liquid (IL) solvents has received tremendous attention by taking advantage of their extraordinary properties. However, the remarkably high viscosity, which makes dispersing the support into the IL a major challenge, has limited their usage to the synthesis of un-supported nanoparticles. As an MSCA fellow, I will receive crucial training at KU Leuven and will work on developing a novel process for the synthesis of supported non-precious metal catalyst using IL. I will synthesize two generations of supported catalysts using novel synthesis procedures. I will produce the one-pot generation (OPG) catalyst by one-pot synthesis of support (zeolite) and metal oxide, whereas the well-structured generation (WSG) catalyst will be made by synthesizing zeolite using the IL as a co-solvent. For the OPG catalyst, both support and metal oxide will be synthesized simultaneously, while for the WSG catalyst, the IL that is used in zeolite synthesis will be re-used to engineer the metal oxide shape. Interestingly, to date the structure sensitivity of the CO2 hydrogenation to methanol and its coupling to DME has not been investigated. I will implement the new catalyst methodology to enhance the catalytic activity and selectivity of CO2 conversion to produce DME and establish synthesis-structure-activity relations.

Keywords: ionic liquid non precious metal oxide zeolite heterogeneous catalysts co2 hydrogenation diethyl ether
Life-long health monitoring and assessment for lifetime maximization of Li-ion batteries (BattMaxLife)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Denmark
Call: MSCA Postdoctoral Fellowships 2022 (HORIZON-MSCA-2022-PF-01, 2022)
Start date: 2023-09-01
End date: 2025-08-31
Duration (months): 24.0
Total project cost (EUR): 230774.4
EU funding (EUR): 230774.4
Participants: 1
Project status: SIGNED

Lithium-ion (Li-ion) batteries have an integrated battery management system (BMS) whose performance is critical in maximizing the available life of the batteries and increasing their sustainability. The BMS monitors state parameters, such as state-of-charge (SOC) and state-of-health (SOH), for safety and performance optimization purposes. The accuracy of these parameters plays a critical role in maximizing the available battery lifetime. This MSCA fellowship project aims to maximize the available lifetime of Li-ion batteries (and subsequently the lifetime of their applications) by making the battery impedance accessible in real-time for the BMS state estimation algorithms by using a novel ternary-sequence impedance measurement method that is integrated onboard the battery pack. The impedance-based SOC and SOH estimation algorithms will offer higher accuracy compared to the available traditional algorithms. Thus, the BMS will be able to optimize the battery's use and consequently maximize its life in its primary application (i.e., first-life application), such as in electric vehicles. Despite lacking the performance for the primary application, the battery is still likely to be used in a less demanding application, i.e., stationary energy storage. With adequate health information available (using the novel impedance-based algorithms) at the end of its first-life, the battery will become an attractive candidate for second-life application, as reliable predictions can be made about its remaining lifetime, safety, and economic value. With first-life maximized and second life provided for the battery pack, the lifetime of the battery is significantly prolonged before the eventual recycling, increasing Li-ion batteries' sustainability This highly innovative project has a high scientific, economic, and societal impact. Furthermore, the project will allow the applicant to enrich his technical and managerial skills thus boosting his career prospects and enlarging his horizon

Keywords: batteries,impedance,state of health estimation,state of charge estimation,battery management systems
Novel WEFE Nexus-based approaches towards agroforestry management in the Greater North African Region (TRANS-SAHARA)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Food, Bioeconomy Natural Resources, Agriculture and Environment
Theme: Bio-Environment
Destination: Fair, healthy and environmentally-friendly food systems from primary production to consumption
Action type: Research and Innovation actions
Countries involved: Germany,Chad,Tunisia,Netherlands,Japan,Belgium,Italy,Ghana,Algeria,Mali,Kenya,Djibouti,Senegal,Spain
Call: EU-African Union cooperation on agroforestry management for climate change adaptation and mitigation (HORIZON-CL6-2024-FARM2FORK-01, 2024)
Start date: 2024-11-01
End date: 2027-10-31
Duration (months): 36.0
Total project cost (EUR): 5489475.0
EU funding (EUR): 5489475.0
Participants: 22
Project status: SIGNED

TRANS-SAHARA will establish a groundbreaking approach for leveraging agroforestry systems to support African communities in their fight against climate change. This innovative approach is based on the well-established Water-Energy-Food-Ecosystems (WEFE) Nexus approach, which emphasizes the primacy of ensuring water security when designing, installing and managing agroforestry systems. The translation of this conceptual agroforestry management approach into real-world applications is supported by an array of technical and non-technical innovations. These include cutting-edge measurement methods and tools to accurately assess environmental and socio-economic impacts, scalable nature-based intervention strategies to facilitate sustainable exploitation of natural resources, and novel business models designed to secure long-term livelihoods of local communities engaged in agroforestry practices. The efficacy of the novel approach and supporting innovations will be rigorously tested and validated through a series of large-scale pilot demonstrations set to take place in key locations across Africa, including Tunisia, Ghana, and Ethiopia. Novel community-led engagement methods are used to support the co-design of the demonstrators, and ensure deep acceptance of the innovation within local communities. Expected outcomes will contribute to bridging the agroforestry data gaps in Africa, increased crop yield, doubling of farmers’ annual incomes, and creation of new carbon sinks across previously degraded territories. An ambitious post-project exploitation plan executed in partnership with EU and African policymakers and civil society groups foresees the immediate and widespread uptake of resulting innovations across African Union (AU) member countries and beyond by 2030. Innovation adopters will significantly enhance their communities’ resilience to threats posed by the climate emergency, and stimulate highly sustainable socio-economic development across their region.

Keywords: water energy food ecosystems wefe nexus climate change mitigation and adaptation synergies climate resilience water security africa socio economic innovation participatory co creation process
Next generation, off-the-shelf, non fratricide-directed, CAR immunotherapy for relapse/refractory T-cell acute lymphoblastic leukemia (CARxALL)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Transition
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Spain,Portugal
Call: EIC Transition Open 2022 (HORIZON-EIC-2022-TRANSITION-01, 2022)
Start date: 2023-04-01
End date: 2026-03-31
Duration (months): 36.0
Total project cost (EUR): 2497500.0
EU funding (EUR): 2497500.0
Participants: 3
Project status: SIGNED

R/R T-ALL remains a major clinical challenge. Despite improved survival rates thanks to intensive chemotherapy regimens, event-free (EFS) and overall (OS) survival remains <70% and R/R T-ALL has a particularly poor outcome. There are currently no potential curative options for R/R T-ALL beyond hematopoietic stem cell transplantation (HSCT) and conventional chemotherapy, which is linked to large trade-offs in toxicities. Sadly, >90% of patients with R/R T-ALL/LL ultimately die. Strategies targeting T-cell malignancies using immunotherapies (including CARTs) remain challenging because of the shared expression of target antigens between normal and malignant T-cells, ultimately leading to life-threatening immunodeficiency due to T-cell aplasia and fratricide of CARTs, which limits their therapeutic efficacy. Here, we propose a unique and innovative approach to address this unmet clinical need based on the dual targeting of two specific antigens with expression restricted to T-cell lymphoblasts. Our consortium aims to provide a cost-effective immunotherapeutic alternative for most of the R/R T-ALL patients by the dual targeting of two tnon-fratricide antigens using our scalable, HLA-independent, allogenic, off-the-shelf, proprietary platform of CORD-GDT cells, thus overcoming the challenges of harvesting sufficient numbers of functional effector T cells from multi-treated patients with advanced disease while avoiding the toxicities derived from other shared antigens between healthy and malignant T cells . Our strategy will be preclinically assayed using cutting-edge experimental models, and we will mature and scale-up the proprietary platform of universal CORD-GDT cells redirected against these two non-fratricide antigens, expected to provide superior effector features and contribute to ad-hoc point-of-care treatment with cost-effective, ready-to-use and off-the-shelf effector cells.

Keywords: car t,t all,cd1 ccr9,cell based therapies
Spintronics based on Ferroelectrics (SpinFerro)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Physics
Countries involved: France
Call: MSCA Postdoctoral Fellowships 2023 (HORIZON-MSCA-2023-PF-01, 2023)
Start date: 2024-10-07
End date: 2026-10-06
Duration (months): 24.0
Total project cost (EUR): 211754.88
EU funding (EUR): 211754.88
Participants: 1
Project status: SIGNED

Current state of the art technologies demand high density and high performance electronic devices with reduced energy consumption. This stretches the performance limits of Complementary Metal Oxide Semiconductor (CMOS) transistors technology. Among the many beyond CMOS approaches, one of the most promising routes is the spintronics ecosystem. In the framework of this project, we aim to investigate a beyond CMOS spintronics device recently proposed and called Ferroelectric Spin Orbit (FESO) device, where the spin polarized states of a Rashba interface are manipulated through its proximity with a ferroelectric material. The project’s innovation relies on the exploitation of this effect to transform spin to charge currents in a controllable manner through the reversing a ferroelectric’s polarization, to develop a new in memory computing technology. The FESO technology involves non-volatility, low operating voltage and much lower energy consumption compared to conventional CMOS and other spintronic devices. As a main scientific objective, the researcher will investigate and understand the effect of the ferroelectric layer to FESO devices performance in terms of materials choice, growth quality, dimensions and compatibility to Ferromagnetic materials. The main technological objective is to fabricate a prototype and characterize its operational performance with regards to cutting edge nanoelectronics standards. The results of the project and key performance of the FESO device will be tabulated in a roadmap. During this project the researcher will be trained in advanced Nanofabrication techniques and device characterization. Except from the research skills, the researcher will also gain experience in a series of transferable skills. This project constitutes a perfect opportunity to establish an independent scientific profile at the frontier of nanoelectronics and semiconductor industry, a key field in the framework of major European Commission initiatives.

Keywords: beyond cmos technologies,in memory computing,ferroelectrics,spintronics,spin to charge conversion,rashba effect,nano fabrication,condensed matter physics,applied physics
Repurposed Drug Neuroprotective Nanocarriers for Targeting Retinal Diseases (RENASCENT)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Italy,Spain
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2025-10-01
End date: 2027-09-30
Duration (months): 24.0
Total project cost (EUR): 193643.28
EU funding (EUR): 193643.28
Participants: 2
Project status: SIGNED

Retinitis pigmentosa is one of the main causes of irreversible blindness worldwide, yet the only intraocular approved treatment, Luxturna®, is suitable for less than 1% of patients. A promising way to tackle this disease is by targeting protein aggregation, a process involved in all forms of retinitis pigmentosa and other brain-related disorders. Most potential treatments are still in early stages, so repurposing existing drugs with known safety records can speed up the development of effective therapies. Tideglusib, a drug initially approved for the treatment of progressive supranuclear palsy, has shown promise in reducing protein aggregation, thereby offering protection against neurodegeneration. However, it needs to reach the retina, its therapeutical target, to be effective. The RENASCENT project aims to create a new treatment for all retinitis pigmentosa patients by developing a cutting-edge formulation to deliver tideglusib to the retina via subconjunctival injection, bypassing the challenges of current intraocular treatments that are poorly tolerated. This MSCA Postdoctoral Fellowship will be conducted over two years at the University of Parma in Italy, under the guidance of Prof. Silvia Pescina, a leading expert in eye drug delivery. The project also includes a collaboration with the University of Alicante (Spain) and a visit to the European Synchrotron Radiation Facility (France) to explore the physical properties and neuroscience aspects of the designed formulation. Alongside the scientific work, there will be communication activities to engage the public and share the findings also to an academic audience, providing valuable experience in Ophthalmology and Pharmaceutical Technology for Dr. Marco Brugnera. This project is a significant opportunity for his career, bridging academic research and industry innovation, and has the potential to make a meaningful impact on the treatment of retinitis pigmentosa.

Keywords: ocular drug delivery,ophthalmic formulations,lipid nanocarriers
Soil remediation of per- and polyfluoroalkyl substances (PFAS) to layered double hydroxides (LDHs) – Development, regeneration and mechanisms for injectable soil encapsulating sorbent (LDH-PFAS-SORP) (LDH-PFAS-SORP)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Environment and Geosciences
Countries involved: Spain
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2026-09-01
End date: 2028-08-31
Duration (months): 24.0
Total project cost (EUR): 209914.56
EU funding (EUR): 209914.56
Participants: 1
Project status: SIGNED

Per- and polyfluorinated substances (PFASs) are a growing global concern due to their persistence, bioaccumulation, and high environmental risk, particularly when they contaminate soil and drinking water sources. Effective remediation techniques are urgently needed. Previous research demonstrated that nano-sized layered double hydroxides (LDHs) show great potential for PFAS sorption and can be used as in-situ, injectable liquids to form permeable active barriers. However, to fully utilize LDHs for remediation, their PFAS sorption capabilities and reaction mechanisms must be better understood. This project aims to explore these mechanisms using advanced analytical chemistry, specifically high-resolution mass spectrometry (HRMS) techniques developed by Dr. Gago-Ferrero’s team at IDAEA-CSIC. The fellowship will provide expertise and training in: 1) chemical analysis, focusing on advanced HRMS-based non-target strategies; 2) the synthesis of advanced physiochemical models; and 3) professional development for academic growth. By combining IDAEA-CSIC’s state-of-the-art analytical chemistry capabilities with the applicant’s expertise in soil remediation, PFAS-SORP aims to develop advanced soil remediation techniques for PFAS. Additionally, real-time material property deterioration will be investigated using EXAFS and XANES analysis at MAXLAB IV. This novel approach to using HRMS to understand molecular mechanisms in environmental engineering will set a new benchmark for future environmental remediation techniques.

Keywords: pfas soil remediation by elucidating and optimizing reaction mechanisms using novel high resolution mass spectometry and big data